Lymphocytic hypophysitis: non-invasive diagnosis and treatment by high dose methylprednisolone pulse therapy?

Rudolf A Kristof, Dirk Van Roost, Dietrich Klingmüller, Wolfram Springer, Johannes Schramm

Abstract
Criteria for the non-invasive diagnosis of lymphocytic hypophysitis (LyHy) and the results of the first prospective trial of high dose methylprednisolone pulse therapy (HDMPT) in nine patients are presented. In three patients, the diagnosis was established histologically, and in the others by clinical and endocrinological assessment, MRI, CSF examination, and measurement of thyroglobulin autoantibody concentration. After HDMPT, adenopituitary function improved in four of the nine patients and diabetes insipidus ceased or improved in all four concerned patients.

The MRI findings improved in seven patients. LyHy has to be considered in the differential diagnosis of sellar lesions. The presumptive non-invasive diagnosis of LyHy seems possible in a high proportion of patients. HDMPT may result in the improvement of clinical, endocrinological, and MRI findings.

Keywords: lymphocytic hypophysitis; high dose methylprednisolone pulse therapy

Lymphocytic hypophysitis (LyHy) is a rare chronic inflammatory disease with little known natural history, usually diagnosed unexpectedly at surgery for presumptive pituitary adenoma. Experience in the treatment of LyHy is scarce. Non-invasive diagnostic criteria and results of standardised HDMPT are presented.

Patients and methods
All patients with LyHy (mean age 41 years, seven women) diagnosed at our institution are reported on. Adenohypophyseal function was dynamically assessed as described by Thorner et al. Neurohypophyseal function was assessed as described by Reeves and Andreoli. Evaluation of the sellar region by MRI was carried out as described by Elster. In the six patients not operated on, CSF was evaluated by white cell count, cytology, global protein content, and neurotropic virus serology (herpes simplex, varicella zoster, mumps). The thyroglobulin autoantibody concentration was measured in four patients. In three patients, LyHy was diagnosed histologically. In the others, differential diagnosis was considered for tuberculosis, sarcoidosis, and syphilis by clinical, laboratory (tuberculin test, angiotensin I converting enzyme measurement, treponema pallidum haemaglutination test), and chest radiography evaluation.

The high dose short lasting methylprednisolone administration aimed at minimising the side effects of chronic corticosteroid therapy and at differentiating therapeutic effects from longterm natural course of LyHy. HDMPT consisted of 120 mg methylprednisolone daily for 2 weeks, followed by a dose reduction to 80, 60, 40, and 20 mg daily for 1 week each. Each patient received one course of HDMPT.

Results were assessed by endocrinology and MRI as presented above, at 3, 6, and 12 month intervals thereafter. The average follow up amounted to 29 (19–38) months.

Literature research was done using the Medline program and the key word hypophysitis.

Results
The patient’s details and courses of disease are listed in the table.

Two of the three patients operated on were only biopsied because the intraoperative findings were inconsistent with an adenoma. The third was mimicking an adenoma and was completely resected. LyHy represented 1.1% of all sellar pathologies sampled by a transsphenoidal approach.

Disease onset was sudden in five (four diabetes insipidus, one local mass effect) and insidious in four (adenopituitary impairment) patients.

The amount of daily urinary excretion in the patients with diabetes insipidus varied between 6 and 12 litres. All patients presented with adenopituitary impairment.

Evaluation of CSF in six patients disclosed a raised cell count of 72 (SD 64) cells/mm³. The global protein content of CSF (72 (SD 18) mg/dl), cytology (lymphomonoxytic cells), and neurotropic virus serology were normal.
Lymphocytic hypophysitis

Findings and courses of nine patients with lymphocytic hypophysitis treated by high dose methylprednisolone pulse therapy

<table>
<thead>
<tr>
<th>Age, sex</th>
<th>Clinical presentation</th>
<th>Laboratory findings</th>
<th>MRI</th>
<th>Biopsy</th>
<th>Follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case 1</td>
<td>23 y, F, 6 years</td>
<td>Impaired pituitary functions: C, G, S, T</td>
<td>Global symmetric enlargement of anterior pituitary lobe with slight suprasellar extension and marked homogeneous contrast enhancement. Thickened, enhancing sellar diaphragm.</td>
<td>Thickened sellar endosteu. Whitish, firm sellar content</td>
<td>38 months. No improvement of pituitary function. Slight shrinkage of enlarged sellar content and pituitary stalk</td>
</tr>
<tr>
<td>Case 2</td>
<td>29 y, F, 4 months</td>
<td>Impaired pituitary functions: C, G, S, L</td>
<td>Global symmetric enlargement of anterior pituitary lobe with suprasellar extension and marked homogeneous contrast enhancement. Thickened and markedly enhancing pituitary stalk</td>
<td>Thickened sellar endosteu. Whitish firm sellar content</td>
<td>36 months. Normalisation of G and S pituitary function, C and L impairment unchanged. Shrinkage of sellar content nearly to an empty sella, shrinkage of thickened pituitary stalk</td>
</tr>
<tr>
<td>Case 3</td>
<td>36 y, F, 6 months</td>
<td>Impaired pituitary functions: G, S</td>
<td>Slightly asymmetric enlargement of anterior pituitary lobe with suprasellar extension and marked homogeneous contrast enhancement. Pituitary stalk of normal appearance.</td>
<td>Reddish inflammatory nodule of firm consistence, delineable from the pituitary.</td>
<td>24 months. Persistent impairment of G, S, L function, postoperatively persistent DI. MRI not evaluable because of extensive surgery 42 months. DI ceased, persistent impairment of S function. Shrinkage of the sellar content, pituitary stalk still somewhat enlarged</td>
</tr>
<tr>
<td>Case 5</td>
<td>40 y, F, 6 months</td>
<td>Impaired pituitary functions: C, G, S, L, CSF: 48 lymphomonocytic cells/mm³, 38 mg/dl global protein content; virus serology negative.</td>
<td>Sellar content of normal extent, posterior lobe not delineable. Homogeneous marked contrast enhancement of the sellar content.</td>
<td>Not done</td>
<td>Shrinkage of sellar content 27 months. Normalisation of C function. Improvement of DI and S impairment. Shrinkage of the thickened pituitary stalk</td>
</tr>
<tr>
<td>Case 6</td>
<td>42 y, F, 1.5 years</td>
<td>Impaired pituitary functions: C, S, D, CSF: 30 lymphomonocytic cells/mm³, 31 mg/dl global protein content; virus serology negative. Thyroglobulin autoantibody concentration not risen.</td>
<td>Pituitary stalk slightly thickened and markedly enhancing</td>
<td>Not done</td>
<td></td>
</tr>
<tr>
<td>Case 7</td>
<td>30 y, M, 2 months</td>
<td>Impaired pituitary functions: C, D, CSF: 33 lymphomonocytic cells/mm³, 54 mg/dl global protein content; virus serology negative. Thyroglobulin autoantibody concentration not risen.</td>
<td>Slight symmetric enlargement of sellar content with prominence of the posterior lobe. Marked and homogeneous contrast enhancement of the sellar content. Pituitary stalk of normal appearance.</td>
<td>Not done</td>
<td>19 months. DI ceased, persistent slight impairment of C function. No change of sellar content</td>
</tr>
<tr>
<td>Case 8</td>
<td>62 y, F, 2 months</td>
<td>Impaired pituitary functions: C, G, S, D, CSF: 198 lympho-monocytic cells/mm³, 56 mg/dl global protein content; virus serology negative. Thyroglobulin autoantibody concentration not risen.</td>
<td>Sellar content of normal extent, posterior lobe not delineable. Marked and homogeneous enhancement of sellar content. Pituitary stalk thickened and strongly enhancing</td>
<td>Not done</td>
<td>19 months. DI ceased, G normalised, S improved, persistent impairment of C function. Shrinkage of pituitary stalk</td>
</tr>
<tr>
<td>Case 9</td>
<td>62 y, F, 1.5 years</td>
<td>Impaired pituitary functions: S, CSF: 45 lympho-monocytic cells/mm³, 75 mg/dl global protein content; virus serology negative. Thyroglobulin autoantibody concentration markedly risen (1935 U/ml).</td>
<td>Global symmetric enlargement of the anterior pituitary lobe with suprasellar extension and marked homogeneous contrast enhancement. Thickened and markedly enhancing pituitary stalk</td>
<td>Not done</td>
<td>19 months. Persistent impairment of S function. Thyroglobulin autoantibody concentration normalised (&lt;400 U/ml). Slight shrinkage of sellar content and of pituitary stalk</td>
</tr>
</tbody>
</table>

C= Corticotroph; T= thyreotroph; G= gonadotroph; S= somatotroph; L= lactotroph.

On plain T1 weighted MRI, the sellar content was slightly to moderately and roughly symmetrically enlarged with suprasellar expansion in seven patients. The posterior lobe was not discernible in two patients. On postcontrast T1 weighted images, the sellar content enhanced strongly and homogeneously in eight patients, and showed a hypointense area in one case. The pituitary stalk was thickened and strongly enhancing in five patients. The presence of a thickened pituitary stalk and the occurrence of diabetes insipidus were not invariably linked.

HDMPT was well tolerated by all patients (a transient rash and an oral mycosis occurred once each). Diabetes insipidus resolved in three patients and improved to the degree of a lesser need of desmopressin in one. In patient 3, diabetes insipidus developed after surgery and was not influenced by HDMPT. Adenopituitary function improved in four out of nine patients and remained unchanged in the others (including patient 3). Hormone replacement could be reduced or stopped in four of seven patients.

Shrinkage of the sellar mass or pituitary stalk was seen on MRI in seven patients (patient 3 not assessable), varying from a slight degree of shrinkage to nearly an empty sella (figure).

**Discussion**

The histological characteristics of LyHy are well established. Its aetiology is unclear, with some evidence for an autoimmunological, possibly virus induced origin.

**DIAGNOSIS**

Up to 1990 43, and up to 1995 72 additional patients were reported on (authors’ review). Probably due to a higher awareness, modern
endocrinology, and neuroimaging, LyHy is diagnosed with increasing frequency, and there is an apparent change in its presentation.

The preponderance of females (98%–79%), often with a peripartum onset (62%–47%) and the sudden onset of diabetes insipidus (“exceptional”–31%) are clinical hallmarks of LyHy. However, the present series suggests that the involvement of the neuropituitary on MRI and diabetes insipidus are not invariably linked. Other manifestations such as headache, chiasm compression, and diplopia (44%, 26%, and 6% respectively) lack specificity.

The adenopituitary impairment was disproportionate to the often small extent of the pituitary mass on MRI in the present series. The impairment (77%–47%) seems to develop earlier in LyHy and more often concerns corticotrophic and thyrotrophic functions (56% and 40%) than in pituitary adenoma, in which the somatotrophic and gonadotrophic functions are usually the first to be impaired.16 19 20

The association with other autoimmuneological diseases in 30% of the patients, usually a thyroiditis, may be a diagnostic hint for LyHy.15

White cell count in the CSF showed a significantly (α=0.05) higher lymphomonocytic pleocytosis in LyHy (72 (SD 64) cells/mm³), compared with seven patients with

Coronal contrast enhanced MRI of lymphocytic hypophysitis before and after HDMPT: marked shrinkage of the sellar content and slight shrinkage of the pituitary stalk after HDMPT in patient 2 (A, B); slight shrinkage of the sellar content and of the pituitary stalk after HDMPT in patient 6 (C, D).
Lymphocytic hypophysitis

histologically confirmed pituitary adenoma (14 (SD 11) cells/mm³). Together with the absence of antiviral antibodies and of clinical meningitis, this slight pleocytosis in LyHy is likely to be an aseptic meningeal reaction to pituitary inflammation.

The symmetric enlargement of sellar content (66%) seen on MRI with thickening of the pituitary stalk (56%), both homogeneously enhancing, were confirmed in 51 patients reviewed from the literature (published 1991 to 1997) in 51% of the patients. Asymmetry of the enlarged sellar content (18%), signal alterations on native T1 weighted (9%) or inhomogeneous contrast enhancement (12%), cavernous sinus and hypothalamus involvement (12%), empty sella (9%), and no pathological findings (9%) have also been described.

Although no single above feature is pathognomonic of LyHy, their simultaneous presence will confer a higher amount of diagnostic reliability. However, some uncertainty will always persist without histological confirmation of the diagnosis.

Differential diagnosis against common sellar tumours, such as pituitary adenomas, craniopharyngiomas, and meningiomas, will focus on the frequent peripartal occurrence, the marked adenopituitary impairment, and frequent presence of diabetes insipidus, the presence of other autoimmuneological diseases, and on the common MRI appearance of LyHy. Differential diagnosis to common sellar inflammations, such as tuberculosis, sarcoidosis, and syphilis, will focus on medical history (usually chronic and previously known diseases), laboratory findings (tuberculin test and antigene polymerase chain reaction in CSF for tuberculosis, angiotensin-I-converting enzyme in plasma for sarcoidosis, treponema pallidum hemagglutination test for syphilis), chest radiography (tuberculous and sarcoidosis), and less upon MRI. In very rare tumours such as histocytosis X and inflammations such as primary granulomatous hypophysitis, differential diagnosis is virtually impossible to establish except by histology. It has been suggested that LyHy and primary granulomatous hypophysitis may be part of the same disease range.² seventeen

TREATMENT

LyHy may become worse due to progressive pituitary insufficiency,¹ five but also may improve spontaneously.¹ five twenty-two Adequate hormone replacement therapy is crucial.

Although LyHy is a chronic inflammatory process, probably of autoimmune aetiology, anti-inflammatory corticosteroid treatment has not been systematically used so far. Thirteen patients in the literature,⁵ nine of them preoperatively, were treated with a mean daily dose of 27.5 mg methylprednisolone equivalent (range 13 to 41 mg, not detailed in three patients) for a mean time of 4.75 months (range 5 days to 19 months). Lasting improvements (endocrinological and neuroradiological) occurred in 15% and transient improvements (also neurological ones) in 62% of the cases. Relapse of symptoms occurred days to a few months after discontinuation of corticosteroid therapy.

The nine patients of this series were treated in a standardised manner by HDMPT. Improvement of adenopituitary function was found in 44% of the patients and was more favourable in cases with short standing disease (6 months or less). In three patients the improvements occurred within 6 weeks and in the fourth within 6 months after HDMPT. Diabetes insipidus ceased in three and improved in one of four patients during HDMPT.

Normalisation or improvement of MRI findings occurred in 88% of the patients, in seven within 6 weeks and in the eight within 6 months after HDMPT. Here, the duration of the disease seemed to be of no importance. Because of the close temporal relation, endocrinological and MRI improvements are most likely attributed to HDMPT and not to a favourable natural course of LyHy which eventually would be expected to occur over months or years.¹ five nineteen twenty-two Neither a relapse of the disease, nor further (spontaneous) improvement, were found in this series.

It remains doubtful whether the results of HDMPT are definitive because follow up is relatively short. Nevertheless, they compare favourably with those reported in the literature and also with the natural course of the disease, the most probable explanation being the regimen of drug application used in this series. On the other hand, complete recovery of the pituitary was achieved in none of our patients. This might be due to a suboptimal regimen of drug application, but also to an already irreversible destruction of the pituitary by LyHy.¹ eleven

Whereas surgery for mass effect in LyHy invariably led to rapid relief of neurological symptoms, endocrinological improvement was seldom reported.¹ In some patients, however, surgery led to worsening of pituitary function or was followed by recurrence of symptoms (patient 3).¹ five seventeen twenty-six Usually the intraoperative findings differ from those of a pituitary adenoma. Quick frozen sections will help to clarify any doubts. In some patients, inflammation may intraoperatively mimick a pituitary adenoma (patient 3).¹ nineteen twenty-One to avoid potential worsening of the pituitary function, surgery should be kept limited when LyHy is suspected intraoperatively and HDMPT should be considered.

In view of recent experience, the presumptive diagnosis of LyHy may be established by conservative evaluation in a high proportion of patients. The presented results suggest a trial of HDMPT under close monitoring of endocrinological, neuro-ophthalmological, and MRI findings. Follow up has to be at short intervals to identify a possible relapse in time. Indications for surgery are the presence of gross chiasm compression, ineffectiveness of corticosteroid therapy, and the impossibility of establishing the diagnosis of LyHy with sufficient certainty by conservative evaluation.
Lymphocytic hypophysitis: non-invasive diagnosis and treatment by high dose methylprednisolone pulse therapy?

Rudolf A Kristof, Dirk Van Roost, Dietrich Klingmüller, Wolfram Springer and Johannes Schramm

*J Neurol Neurosurg Psychiatry* 1999 67: 398-402
doi: 10.1136/jnnp.67.3.398

Updated information and services can be found at:
http://jnnp.bmj.com/content/67/3/398

These include:

**References**
This article cites 21 articles, 1 of which you can access for free at:
http://jnnp.bmj.com/content/67/3/398#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Immunology (including allergy) (1943)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/